Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
NCT ID: NCT01700400
Last Updated: 2014-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
13 participants
INTERVENTIONAL
2012-09-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be entered onto dosing cohorts of 3 patients according to the following dose escalation scheme. The first cohort will begin at dose level 1. At least three patients on each dose level must have completed cycle one before the study leadership (principal investigators, study statisticians) will allow patients to be enrolled onto the successive dose level.
Dose Levels: 1, 2, 3
Pemetrexed (mg/m²): 500, 500, 500
Carboplatin (AUC): 5, 6, 6
Bevacizumab (mg/kg): 15, 15, 15
Everolimus (mg/day): 2.5, 2.5, 5.0
The purpose of this study is to determine the maximum tolerated dose, or MTD, for the combination of everolimus with pemetrexed, carboplatin, and bevacizumab in patients with Stage IV non-squamous, non small cell lung cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental Phase I Dose Escalation
Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3
Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3
Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3
Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3
Everolimus
Pemetrexed
Carboplatin
Bevacizumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Everolimus
Pemetrexed
Carboplatin
Bevacizumab
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Confirmed diagnosis of Stage IV non-squamous non-small cell lung cancer
3. CT of the chest, abdomen, and pelvis which shows metastatic disease. If the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation.
4. At least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation.
5. Age ≥ 18 years
6. Normal blood function levels as evidenced by laboratory tests.
7. Adequate liver, kidney and blood chemistry function.
8. Adequate blood clotting levels
9. Urine dipstick levels of protein must be between 0-1+.
10. Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 x IULN. Testing must be performed within 14 days prior to enrollment.
11. The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed.
12. No prior treatment with everolimus. Prior treatment with pemetrexed or carboplatin is allowed, provided no disease progression with prior exposure to drugs. Prior treatment with bevacizumab allowed.
Exclusion Criteria
2. Clinically significant cardiac event such as Myocardial infarction
3. Inadequately controlled high blood pressure
4. Active gastrointestinal disease resulting in an inability to take oral or enteral medication via a feeding tube or a requirement for IVplacement; prior surgical procedures affecting absorption; or active peptic ulcer disease
5. Presence of fluid accumulation which cannot be controlled by drainage
6. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to enrollment
7. History of stroke within 6 months prior to enrollment
8. History of significant vascular disease within 6 months prior to enrollment(i.e., aortic aneurysm)
9. No unusual bleeding or inability to clot (assuming not on anti-coagulation); patients with a history of DVT and/pr pulmonary embolism are excluded
10. Serious non-healing wound, ulcer, or bone fracture
11. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1.
12. Untreated brain metastases Radiation treatment than 28 days prior to registration. Side effects due to radiation therapy must have resolved.
13. Coughing up of blood
14. Excessive protein in your urine
15. Abnormal levels of lipids in your blood
16. Previous or current malignancies within the last 3 years, with the exception of cervical cancer and adequately treated basal cell or squamous cell carcinoma of the skin
17. Prior treatment with any investigational drug within the preceding 4 weeks prior to enrollment
18. Patients receiving chronic, systemic treatment with corticosteroids or another immunotherapy. Topical or inhaled corticosteroids are allowed.
19. Patients must not receive immunization with attenuated live vaccines within one week prior to study enrollment or during study period.
20. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation.
21. HIV positive
22. Impairment of stomach or intestinal function or stomach or intestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
23. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus.
24. Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus)
25. Patients with a known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to its excipients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Arizona
OTHER
Providence Cancer Center, Earle A. Chiles Research Institute
OTHER
Novartis Pharmaceuticals
INDUSTRY
Cancer Research and Biostatistics Clinical Trials Consortium
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Linda L. Garland, MD
Role: PRINCIPAL_INVESTIGATOR
University of Arizona
John Crowley, PhD
Role: STUDY_CHAIR
Cancer Research And Bioststistics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arizona Cancer Center
Tuscon, Arizona, United States
University of Kentucky Markey Cancer Center
Lexington, Kentucky, United States
Providence Cancer Center
Portland, Oregon, United States
Cancer Research And Biostatistics Clinical Trials Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Providence Cancer Center of Portland, Oregon
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRAB CTC 10-001
Identifier Type: -
Identifier Source: org_study_id